Please use this identifier to cite or link to this item:
http://hdl.handle.net/11718/26008
Title: | Generic competition and the incentives for early-stage pharmaceutical innovation |
Authors: | Branstetter, Lee Chatterjee, Chirantan Higgins, Matthew J. |
Keywords: | Pharmaceutical innovation;Generic entry;Nature of innovation;Innovation policy |
Issue Date: | 1-Dec-2022 |
Publisher: | Elsevier |
Citation: | Branstetter, L., Chatterjee, C., & Higgins, M. J. (2022). Generic competition and the incentives for early-stage pharmaceutical innovation. Research Policy, 51(10), 104595. https://doi.org/10.1016/J.RESPOL.2022.104595 |
Abstract: | What impact has rising generic competition had on the nature and direction of pharmaceutical innovation? We find broad-based, strong evidence that pharmaceutical companies have diverted their new drug development efforts away from therapeutic markets already well-served by generic drugs. We also find that increasing generic competition induces firms to shift their R&D activity toward more biologic-based products and away from chemical-based products. We conclude by discussing potential implications of our results for long-run innovation policy. |
URI: | http://hdl.handle.net/11718/26008 |
ISSN: | 0048-7333 |
Appears in Collections: | Journal Articles |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
Generic_competition_and_the_incentives_for_early-stage_pharmaceutical_innovation.pdf Restricted Access | Generic_competition_and_the_incentives_for_early-stage_pharmaceutical_innovation | 729.04 kB | Adobe PDF | View/Open Request a copy |
Items in IIMA Institutional Repository are protected by copyright, with all rights reserved, unless otherwise indicated.